RET tyrosine kinase signaling in development and cancer

Cytokine and Growth Factor Reviews

Volumn 16, Issue 4-5, 2005, Pages 441-467

  Arighi, Elena ^a,b   Borrello, Maria Grazia ^b   Sariola, Hannu ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

GDNF; Hirschsprung's disease; Multiple endocrine neoplasia type 2; RET; Thyroid cancer

Indexed keywords

ALLYLGELDANAMYCIN; ARYLIDEN 2 INDOLINONE; CEP 701; CEP 751; FIBROBLAST GROWTH FACTOR RECEPTOR; GELDANAMYCIN; GENISTEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; IMATINIB; INDOLE DERIVATIVE; LIGAND; PD 173074; PROTEIN INHIBITOR; PROTEIN RET; PROTEIN TYROSINE KINASE; PYRAZOLOPYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RADIOACTIVE IODINE; RECEPTOR; UNCLASSIFIED DRUG; VANDETANIB;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; DEVELOPMENT; FAMILIAL CANCER; GENE; GENE ACTIVATION; GENE MUTATION; GENETIC ANALYSIS; HIRSCHSPRUNG DISEASE; HORMONE DETERMINATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE ENDOCRINE NEOPLASIA; MUTATIONAL ANALYSIS; NEUROFIBROMATOSIS; NONHUMAN; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIPPLE SYNDROME; THYROID CARCINOMA; THYROID GLAND; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

HIRSCHSPRUNG DISEASE; HUMANS; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 22544456020     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2005.05.010     Document Type: Review

References (372)

1. V. Pachnis, B. Mankoo, and F. Costantini Expression of the c-ret proto-oncogene during mouse embryogenesis Development 19 1993 1005 1017
2. V. Avantaggiato, N.A. Dathan, M. Grieco, N. Fabien, D. Lazzaro, and A. Fusco Developmental expression of the RET protooncogene Cell Growth Differ 5 1994 305 311
3. A. Schuchardt, V. D'Agati, L. Larsson-Blomberg, F. Costantini, and V. Pachnis Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret Nature 367 1994 380 383
4. P.L. Durbec, L.B. Larsson-Blomberg, A. Schuchardt, F. Costantini, and V. Pachnis Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts Development 122 1996 349 358
5. X. Meng, M. Lindahl, M.E. Hyvönen, M. Parvinen, D.G. de Rooij, and M.W. Hess Regulation of cell fate decision of undifferentiated spermatogonia by GDNF Science 287 2000 1489 1493
6. S. Jain, C.K. Naughton, M. Yang, A. Strickland, K. Vij, and M. Encinas Mice expressing a dominant-negative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis Development 131 2004 5503 5513
7. P. Edery, S. Lyonnet, L.M. Mulligan, A. Pelet, E. Dow, and L. Abel Mutations of the RET proto-oncogene in Hirschsprung's disease Nature 367 1994 378 380
8. G. Romeo, P. Ronchetto, Y. Luo, V. Barone, M. Seri, and I. Ceccherini Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease Nature 367 1994 377 378
9. M. Grieco, M. Santoro, M.T. Berlingieri, R.M. Melillo, R. Donghi, and I. Bongarzone PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas Cell 60 1990 557 563
10. M. Santoro, G. Chiappetta, A. Cerrato, D. Salvatore, L. Zhang, and G. Manzo Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice Oncogene 12 1996 1821 1826
11. S.M. Jhiang, J.E. Sagartz, Q. Tong, J. Parker-Thornburg, C.C. Capen, and J.Y. Cho Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas Endocrinology 137 1996 375 378
12. J.R. Hansford, and L.M. Mulligan Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis J Med Genet 37 2000 817 827
13. M. Takahashi, J. Ritz, and G.M. Cooper Activation of a novel human transforming gene, ret, by DNA rearrangement Cell 42 1985 581 588
14. Y. Ishizaka, F. Itoh, T. Tahira, I. Ikeda, T. Sugimura, and J. Tucker Human ret proto-oncogene mapped to chromosome 10q11.2 Oncogene 4 1989 1519 1521
15. M. Hahn, and J. Bishop Expression pattern of Drosophila ret suggests a common ancestral origin between the metamorphosis precursors in insect endoderm and the vertebrate enteric neurons Proc Natl Acad Sci USA 98 2001 1053 1058
16. M. Takahashi, and G.M. Cooper ret transforming gene encodes a fusion protein homologous to tyrosine kinases Mol Cell Biol 7 1987 1378 1385
17. M. Takahashi, Y. Buma, T. Iwamoto, Y. Inaguma, H. Ikeda, and H. Hiai Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains Oncogene 3 1988 571 578
18. M. Takahashi, Y. Buma, and H. Hiai Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence Oncogene 4 1989 805 806
19. T. Iwamoto, M. Taniguchi, N. Asai, K. Ohkusu, I. Nakashima, and M. Takahashi cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily Oncogene 8 2001 1087 1091
20. J. Anders, S. Kjær, and C.F. Ibáñez Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site J Biol Chem 276 2001 35808 35817
21. B.A. Ponder The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome Cancer Res 59 1999 1736s 1741s
22. M. Takahashi, Y. Buma, and M. Taniguchi Identification of the ret proto-oncogene products in neuroblastoma and leukemia cells Oncogene 6 1991 297 301
23. M. Takahashi, N. Asai, T. Iwashita, T. Isomura, K. Miyazaki, and M. Matsuyama Characterization of the ret proto-oncogene products expressed in mouse L cells Oncogene 8 1993 2925 2929
24. T. Tahira, Y. Ishizaka, F. Itoh, T. Sugimura, and M. Nagao Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line Oncogene 5 1990 97 102
25. S.M. Myers, C. Eng, B.A. Ponder, and L.M. Mulligan Characterization of RET proto-oncogene 3′ splicing variants and polyadenylation sites: a novel C-terminus for RET Oncogene 11 1995 2039 2045
26. M.T. Carter, J.L. Yome, M.N. Marcil, C.A. Martin, J.B. Vanhorne, and L.M. Mulligan Conservation of RET proto-oncogene splicing variants and implications for RET isoform function Cytogenet Cell Genet 95 2001 169 176
27. B.A. Tsui-Pierchala, R.C. Ahrens, R.J. Crowder, J. Milbrandt, and EM. Johnson Jr. The long and short isoforms of Ret function as independent signaling complexes J Biol Chem 277 2002 34618 34625
28. M.G. Borrello, E. Mercalli, C. Perego, D. Degl'Innocenti, S. Ghizzoni, and E. Arighi Differential interaction of Enigma protein with the two RET isoforms Biochem Biophys Res Commun 296 2002 515 522
29. D. Degl'Innocenti, E. Arighi, A. Popsueva, R. Sangregorio, L. Alberti, and M.G. Rizzetti Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branching Oncogene 23 2004 7297 7309
30. G. Schuetz, M. Rosario, J. Grimm, T.M. Boeckers, E.D. Gundelfinger, and W. Birchmeier The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells J Cell Biol 167 2004 945 952
31. R.P. Scott, S. Eketjall, H. Aineskog, and C.F. Ibanez Distinct turnover of alternatively-spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase J Biol Chem 280 2005 13442 13449
32. E. de Graaff, S. Srinivas, C. Kilkenny, V. D'Agati, B.S. Mankoo, and F. Costantini Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis Genes Dev 15 2001 2433 2444
33. S. Srinivas, Z. Wu, C.M. Chen, V. D'Agati, and F. Costantini Dominant effects of RET receptor misexpression and ligand-independent RET signaling on ureteric bud development Development 126 1999 1375 1386
34. D.C. Lee, K.W. Chan, and S.Y. Chan RET receptor tyrosine kinase isoforms in kidney function and disease Oncogene 21 2002 5582 5592
35. P. Durbec, C.V. Marcos-Gutierrez, C. Kilkenny, M. Grigoriou, K. Wartiowaara, and P. Suvanto GDNF signalling through the Ret receptor tyrosine kinase Nature 381 1996 789 793
36. M. Trupp, E. Arenas, M. Fainzilber, A.S. Nilsson, B.A. Sieber, and M. Grigoriou Functional receptor for GDNF encoded by the c-ret proto-oncogene Nature 381 1996 785 789
37. S. Jing, D. Wen, Y. Yu, P.L. Holst, Y. Luo, and M. Fang GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF Cell 85 1996 1113 1124
38. J.J. Treanor, L. Goodman, F. de Sauvage, D.M. Stone, K.T. Poulsen, and C.D. Beck Characterization of a multicomponent receptor for GDNF Nature 382 1996 80 83
39. Q.C. Vega, C.A. Worby, M.S. Lechner, J.E. Dixon, and G.R. Dressler Glial cell line-derived neurotrophic factor activates the receptor tyrosine kinase RET and promotes kidney morphogenesis Proc Natl Acad Sci USA 93 1996 10657 10661
40. P.T. Kotzbauer, P.A. Lampe, R.O. Heuckeroth, J.P. Golden, D.J. Creedon, and E.M. Johnson Jr. Neurturin, a relative of glial-cell-line-derived neurotrophic factor Nature 384 1996 467 470
41. J. Milbrandt, F.J. de Sauvage, T.J. Fahrner, R.H. Baloh, M.L. Leitner, and M.G. Tansey Persephin, a novel neurotrophic factor related to GDNF and neurturin Neuron 20 1998 245 253
42. R.H. Baloh, M.G. Tansey, P.A. Lampe, T.J. Fahrner, H. Enomoto, and K.S. Simburger Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex Neuron 21 1998 1291 1302
43. M.S. Airaksinen, A. Titievsky, and M. Saarma GDNF family neurotrophic factor signaling: four masters, one servant? Mol Cell Neurosci 13 1999 313 325
44. M. Saarma, and H. Sariola Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF) Microsc Res Tech 45 1999 292 302
45. R.H. Baloh, H. Enomoto, E.M. Johnson Jr., and J. Milbrandt The GDNF family ligands and receptors - implications for neural development Curr Opin Neurobiol 10 2000 103 110
46. M. Saarma GDNF - a stranger in the TGF-beta superfamily? Eur J Biochem 267 2000 6968 6971
47. L.F. Lin, D.H. Doherty, J.D. Lile, S. Bektesh, and F. Collins GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 260 1993 1130 1132
48. A. Tomac, E. Lindqvist, L.F. Lin, S.O. Ogren, D. Young, and B.J. Hoffer Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo Nature 373 1995 335 339
49. C.E. Henderson, H.S. Phillips, R.A. Pollock, A.M. Davies, C. Lemeulle, and M. Armanini GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle Science 266 1994 1062 1064
50. A.D. Zurn, E.E. Baetge, J.P. Hammang, S.A. Tan, and P. Aebischer Glial cell line-derived neurotrophic factor (GDNF), a new neurotrophic factor for motoneurones Neuroreport 6 1994 113 118
51. R.W. Oppenheim, L.J. Houenou, J.E. Johnson, L.F. Lin, L. Li, and A.C. Lo Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF Nature 373 1995 344 346
52. Q. Yan, C. Matheson, and O.T. Lopez In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons Nature 373 1995 341 344
53. E. Arenas, M. Trupp, P. Akerud, and C.F. Ibáñez GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo Neuron 15 1995 1465 1473
54. A. Buj-Bello, V.L. Buchman, A. Horton, A. Rosenthal, and A.M. Davies GDNF is an age-specific survival factor for sensory and autonomic neurons Neuron 15 1995 821 828
55. T. Ebendal, A. Tomac, B.J. Hoffer, and L. Olson Glial cell line-derived neurotrophic factor stimulates fiber formation and survival in cultured neurons from peripheral autonomic ganglia J Neurosci Res 40 1995 276 284
56. M. Trupp, M. Ryden, H. Jornvall, H. Funakoshi, T. Timmusk, and E. Arenas Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons J Cell Biol 130 1995 137 148
57. S. Manié, M. Santoro, A. Fusco, and M. Billaud The RET receptor: function in development and dysfunction in congenital malformation Trends Genet 17 2001 580 589
58. M.S. Airaksinen, and M. Saarma The GDNF family: signalling, biological functions and therapeutic value Nat Rev Neurosci 3 2002 383 394
59. J.G. Pichel, L. Shen, H.Z. Sheng, A.C. Granholm, J. Drago, and A. Grinberg Defects in enteric innervation and kidney development in mice lacking GDNF Nature 382 1996 73 76
60. M.W. Moore, R.D. Klein, I. Farinas, H. Sauer, M. Armanini, and H. Phillips Renal and neuronal abnormalities in mice lacking GDNF Nature 382 1996 76 79
61. K. Sainio, P. Suvanto, J. Davies, J. Wartiovaara, K. Wartiovaara, and M. Saarma Glial-cell-line-derived neurotrophic factor is required for bud initiation from ureteric epithelium Development 124 1997 4077 4087
62. H. Sariola, and M. Saarma GDNF and its receptors in the regulation of the ureteric branching Int J Dev Biol 43 1999 413 418
63. C.F. Ibáñez Emerging themes in structural biology of neurotrophic factors Trends Neurosci 21 1998 438 444
64. J.F. Hamilton, P.F. Morrison, M.Y. Chen, J. Harvey-White, R.S. Pernaute, and H. Phillips Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin Exp Neurol 168 2001 155 161
65. R.H. Baloh, M.G. Tansey, J.P. Golden, D.J. Creedon, R.O. Heuckeroth, and C.L. Keck TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret Neuron 18 1997 793 802
66. S. Jing, Y. Yu, M. Fang, Z. Hu, P.L. Holst, and T. Boone GFRalpha-2 and GFRalpha-3 are two new receptors for ligands of the GDNF family J Biol Chem 272 1997 33111 33117
67. M. Lindahl, D. Poteryaev, L. Yu, U. Arumäe, T. Timmusk, and I. Bongarzone Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells J Biol Chem 276 2001 9344 9351
68. M. Coulpier, J. Anders, and C.F. Ibáñez Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase: importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival J Biol Chem 277 2002 1991 1999
69. H. Sariola, and M. Saarma Novel functions and signalling pathways for GDNF J Cell Sci 116 2003 3855 3862
70. S. Eketjäll, M. Fainzilber, J. Murray-Rust, and C.F. Ibáñez Distinct structural elements in GDNF mediate binding to GFRalpha1 and activation of the GFRalpha1-c-Ret receptor complex EMBO J 18 1999 5901 5910
71. K. Simons, and E. Ikonen Functional rafts in cell membranes Nature 387 1997 569 572
72. E. Ikonen, and K. Simons Protein and lipid sorting from the trans-Golgi network to the plasma membrane in polarized cells Semin Cell Dev Biol 9 1998 503 509
73. K. Simons, and D. Toomre Lipid rafts and signal transduction Nat Rev Mol Cell Biol 1 2000 31 39
74. D. Poteryaev, A. Titievsky, Y.F. Sun, J. Thomas-Crusells, M. Lindahl, and M. Billaud GDNF triggers a novel ret-independent Src kinase family-coupled signaling via a GPI-linked GDNF receptor alpha1 FEBS Lett 463 1999 63 66
75. M.G. Tansey, R.H. Baloh, J. Milbrandt, and EM. Johnson Jr. GFRalpha-mediated localization of RET to lipid rafts is required for effective downstream signaling, differentiation, and neuronal survival Neuron 25 2000 611 623
76. M. Trupp, N. Belluardo, H. Funakoshi, and C.F. Ibáñez Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS J Neurosci 17 1997 3554 3567
77. T. Yu, S. Scully, Y. Yu, G.M. Fox, S. Jing, and R. Zhou Expression of GDNF family receptor components during development: implications in the mechanisms of interaction J Neurosci 18 1998 4684 4696
78. R.D. Klein, D. Sherman, W.H. Ho, D. Stone, G.L. Bennett, and B. Moffat A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor Nature 387 1997 717 721
79. D.S. Worley, J.M. Pisano, E.D. Choi, L. Walus, C.A. Hession, and R.L. Cate Developmental regulation of GDNF response and receptor expression in the enteric nervous system Development 127 2000 4383 4393
80. G. Paratcha, F. Ledda, L. Baars, M. Coulpier, V. Besset, and J. Anders Released GFRalpha1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment of c-Ret to lipid rafts Neuron 29 2001 171 184
81. G. Paratcha, and C.F. Ibáñez Lipid rafts and the control of neurotrophic factor signaling in the nervous system: variations on a theme Curr Opin Neurobiol 12 2002 542 549
82. B.A. Tsui-Pierchala, M. Encinas, J. Milbrandt, and EM. Johnson Jr. Lipid rafts in neuronal signaling and function Trends Neurosci 25 2002 412 417
83. J. Yang, M. Lindahl, P. Lindholm, H. Virtanen, E. Coffey, and P. Runeberg-Roos PSPN/GFRalpha4 has a significantly weaker capacity than GDNF/GFRalpha1 to recruit RET to rafts, but promotes neuronal survival and neurite outgrowth FEBS Lett 569 2004 267 271
84. H. Peterziel, K. Unsicker, and K. Krieglstein TGFbeta induces GDNF responsiveness in neurons by recruitment of GFRalpha1 to the plasma membrane J Cell Biol 159 2002 157 167
85. M.W. Barnett, C.E. Fisher, G. Perona-Wright, and J.A. Davies Signalling by glial cell line-derived neurotrophic factor (GDNF) requires heparan sulphate glycosaminoglycan J Cell Sci 115 2002 4495 4503
86. M. Tanaka, H. Xiao, and K. Kiuchi Heparin facilitates glial cell line-derived neurotrophic factor signal transduction Neuroreport 13 2002 1913 1916
87. J. Davies, M. Lyon, J. Gallagher, and D. Garrod Sulphated proteoglycan is required for collecting duct growth and branching but not nephron formation during kidney development Development 121 1995 1507 1517
88. S.L. Bullock, J.M. Fletcher, R.S. Beddington, and V.A. Wilson Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase Genes Dev 12 1998 1894 1906
89. J. Ylikoski, U. Pirvola, J. Virkkala, P. Suvanto, X.Q. Liang, and E. Magal Guinea pig auditory neurons are protected by glial cell line-derived growth factor from degeneration after noise trauma Heart Res 124 1998 17 26
90. Z. Kokaia, M.S. Airaksinen, A. Nanobashvili, E. Larsson, E. Kujamaki, and O. Lindvall GDNF family ligands and receptors are differentially regulated after brain insults in the rat Eur J Neurosci 11 1999 1202 1216
91. M. Trupp, R. Scott, S.R. Whittemore, and C.F. Ibáñez Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells J Biol Chem 274 1999 20885 20894
92. A. Popsueva, D. Poteryaev, E. Arighi, X. Meng, A. Angers-Loustau, and D. Kaplan GDNF promotes tubulogenesis of GFRalpha1-expressing MDCK cells by Src-mediated phosphorylation of Met receptor tyrosine kinase J Cell Biol 161 2003 119 129
93. G. Paratcha, F. Ledda, and C.F. Ibáñez The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands Cell 113 2003 867 879
94. C.C. Chao, Y.L. Ma, K.Y. Chu, and E.H. Lee Integrin alphav and NCAM mediate the effects of GDNF on DA neuron survival, outgrowth, DA turnover and motor activity in rats Neurobiol Aging 24 2003 105 116
95. H. Enomoto, I. Hughes, J. Golden, R.H. Baloh, S. Yonemura, and R.O. Heuckeroth GFRalpha1 expression in cells lacking RET is dispensable for organogenesis and nerve regeneration Neuron 44 2004 623 636
96. B.A. Tsui-Pierchala, J. Milbrandt, and EM. Johnson Jr. NGF utilizes c-Ret via a novel GFL-independent, inter-RTK signaling mechanism to maintain the trophic status of mature sympathetic neurons Neuron 33 2002 261 273
97. A. Schuchardt, V. D'Agati, V. Pachnis, and F. Costantini Renal agenesis and hypodysplasia in ret-k-mutant mice result from defects in ureteric bud development Development 122 1996 1919 1929
98. G. Cacalano, I. Farinas, L.C. Wang, K. Hagler, A. Forgie, and M. Moore GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney Neuron 21 1998 53 62
99. H. Enomoto, T. Araki, A. Jackman, R.O. Heuckeroth, W.D. Snider, and E.M. Johnson Jr. GFR alpha1-deficient mice have deficits in the enteric nervous system and kidneys Neuron 21 1998 317 324
100. S. Taraviras, C.V. Marcos-Gutierrez, P. Durbec, H. Jani, M. Grigoriou, and M. Sukumaran Signalling by the RET receptor tyrosine kinase and its role in the development of the mammalian enteric nervous system Development 126 1999 2785 2797
101. C. Marcos, and V. Pachnis The effect of the ret-mutation on the normal development of the central and parasympathetic nervous systems Int J Dev Biol (Suppl) 1 1996 137S 138S
102. H. Enomoto, R.O. Heuckeroth, J.P. Golden, E.M. Johnson, and J. Milbrandt Development of cranial parasympathetic ganglia requires sequential actions of GDNF and neurturin Development 127 2000 4877 4889
103. J. Rossi, A. Tomac, M. Saarma, and M.S. Airaksinen Distinct roles for GFRalpha1 and GFRalpha2 signalling in different cranial parasympathetic ganglia in vivo Eur J Neurosci 12 2000 3944 3952
104. T. Tsuzuki, M. Takahashi, N. Asai, T. Iwashita, M. Matsuyama, and J. Asai Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues Oncogene 10 1995 191 198
105. H.M. Young, C.J. Hearn, D. Ciampoli, B.R. Southwell, J.F. Brunet, and D.F. Newgreen A single rostrocaudal colonization of the rodent intestine by enteric neuron precursors is revealed by the expression of Phox2b, Ret, and p75 and by explants grown under the kidney capsule or in organ culture Dev Biol 202 1998 67 84
106. D.L. Bennett, G.J. Michael, N. Ramachandran, J.B. Munson, S. Averill, and Q. Yan A distinct subgroup of small DRG cells express GDNF receptor components and GDNF is protective for these neurons after nerve injury J Neurosci 18 1998 3059 3072
107. L. Saxén, and H. Sariola Early organogenesis of the kidney Pediatr Nephrol 1 1987 385 392
108. E.A. Cho, and G.R. Dressler Formation and development of nephrons P. Vize A.S. Woolf J.B.L. Bard The kidney: from normal development to congenital disease 2003 Academic Press London 195 210
109. H. Sariola, K. Sainio, and J. Bard Fates of the metanephric mesenchyme P. Vize A.S. Woolf Bard JBL The kidney: from normal development to congenital disease 2003 Academic Press London 181 193
110. H.L. Hellmich, L. Kos, E.S. Cho, K.A. Mahon, and A. Zimmer Embryonic expression of glial cell-line derived neurotrophic factor (GDNF) suggests multiple developmental roles in neural differentiation and epithelial- mesenchymal interactions Mech Dev 54 1996 95 105
111. P. Suvanto, J.O. Hiltunen, U. Arumäe, M. Moshnyakov, H. Sariola, and K. Sainio Localization of glial cell line-derived neurotrophic factor (GDNF) mRNA in embryonic rat by in situ hybridization Eur J Neurosci 8 1996 816 822
112. R. Shakya, T. Watanabe, and F. Costantini The role of GDNF/Ret signaling in ureteric bud cell fate and branching morphogenesis Dev Cell 8 2005 65 74
113. M.A. Basson, S. Akbulut, J. Watson-Johnson, R. Simon, T.J. Carroll, and R. Shakya Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction Dev Cell 8 2005 229 239
114. J. Qiao, H. Sakurai, and S.K. Nigam Branching morphogenesis independent of mesenchymal-epithelial contact in the developing kidney Proc Natl Acad Sci USA 96 1999 7330 7335
115. I. Pavlov, V. Voikar, M. Kaksonen, S.E. Lauri, A. Hienola, and T. Taira Role of heparin-binding growth-associated molecule (HB-GAM) in hippocampal LTP and spatial learning revealed by studies on overexpressing and knockout mice Mol Cell Neurosci 20 2002 330 342
116. R.O. Heuckeroth, H. Enomoto, J.R. Grider, J.P. Golden, J.A. Hanke, and A. Jackman Gene targeting reveals a critical role for neurturin in the development and maintenance of enteric, sensory, and parasympathetic neurons Neuron 22 1999 253 263
117. J. Rossi, K. Luukko, D. Poteryaev, A. Laurikainen, Y.F. Sun, and T. Laakso Retarded growth and deficits in the enteric and parasympathetic nervous system in mice lacking GFR alpha2, a functional neurturin receptor Neuron 22 1999 243 252
118. H. Cremer, R. Lange, A. Christoph, M. Plomann, G. Vopper, and J. Roes Inactivation of the N-CAM gene in mice results in size reduction of the olfactory bulb and deficits in spatial learning Nature 367 1994 455 459
119. M.C. Hofmann, L. Braydich-Stolle, and M. Dym Isolation of male germ-line stem cells; influence of GDNF Dev Biol 279 2005 114 124
120. X. Meng, I. Pata, E. Pedrono, A. Popsueva, D.G. de Rooij, and M. Janne Transient disruption of spermatogenesis by deregulated expression of neurturin in testis Mol Cell Endocrinol 184 2001 33 39
121. X. Liu, Q.C. Vega, R.A. Decker, A. Pandey, C.A. Worby, and J.E. Dixon Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities J Biol Chem 271 1996 5309 5312
122. S. Xing, T.L. Furminger, Q. Tong, and S.M. Jhiang Signal transduction pathways activated by RET oncoproteins in PC12 pheochromocytoma cells J Biol Chem 273 1998 4909 4914
123. D. Salvatore, M.V. Barone, G. Salvatore, R.M. Melillo, G. Chiappetta, and A. Mineo Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins J Clin Endocrinol Metab 85 2000 3898 3907
124. Y. Kawamoto, K. Takeda, Y. Okuno, Y. Yamakawa, Y. Ito, and R. Taguchi Identification of RET autophosphorylation sites by mass spectrometry J Biol Chem 279 2004 14213 14224
125. A. Pandey, H. Duan, P.P. Di Fiore, and V.M. Dixit The Ret receptor protein tyrosine kinase associates with the SH2-containing adapter protein Grb10 J Biol Chem 270 1995 21461 21463
126. A. Pandey, X. Liu, J.E. Dixon, P.P. Di Fiore, and V.M. Dixit Direct association between the Ret receptor tyrosine kinase and the Src homology 2-containing adapter protein Grb7 J Biol Chem 271 1996 10607 10610
127. M. Encinas, R.J. Crowder, J. Milbrandt, and E.M. Johnson Jr. Tyrosine 981, a novel ret autophosphorylation site, binds c-Src to mediate neuronal survival J Biol Chem 279 2004 18262 18269
128. M.G. Borrello, L. Alberti, E. Arighi, I. Bongarzone, C. Battistini, and A. Bardelli The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma Mol Cell Biol 16 1996 2151 2163
129. L. Alberti, M.G. Borrello, S. Ghizzoni, F. Torriti, M.G. Rizzetti, and M.A. Pierotti Grb2 binding to the different isoforms of Ret tyrosine kinase Oncogene 17 1998 1079 1087
130. T. Iwashita, N. Asai, H. Murakami, M. Matsuyama, and M. Takahashi Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN 2A or MEN 2B mutation Oncogene 12 1996 481 487
131. N. Asai, H. Murakami, T. Iwashita, and M. Takahashi A mutation at tyrosine 1062 in MEN 2A-Ret and MEN 2B-Ret impairs their transforming activity and association with shc adaptor proteins J Biol Chem 271 1996 17644 17649
132. K. Durick, R.Y. Wu, G.N. Gill, and S.S. Taylor Mitogenic signaling by Ret/ptc2 requires association with enigma via a LIM domain J Biol Chem 271 1996 12691 12694
133. E. Arighi, L. Alberti, F. Torriti, S. Ghizzoni, M.G. Rizzetti, and G. Pelicci Identification of Shc docking site on Ret tyrosine kinase Oncogene 14 1997 773 782
134. M.J. Lorenzo, G.D. Gish, C. Houghton, T.J. Stonehouse, T. Pawson, and B.A. Ponder RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2 Oncogene 14 1997 763 771
135. M. Ohiwa, H. Murakami, T. Iwashita, N. Asai, Y. Iwata, and T. Imai Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations Biochem Biophys Res Commun 237 1997 747 751
136. A.M. Hennige, R. Lammers, D. Arlt, W. Hoppner, V. Strack, and G. Niederfellner Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells Mol Cell Endocrinol 167 2000 69 76
137. K. Kurokawa, T. Iwashita, H. Murakami, H. Hayashi, K. Kawai, and M. Takahashi Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction Oncogene 20 2001 1929 1938
138. R.M. Melillo, M. Santoro, S.H. Ong, M. Billaud, A. Fusco, and Y.R. Hadari Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade Mol Cell Biol 21 2001 4177 4187
139. R.M. Melillo, F. Carlomagno, G. De Vita, P. Formisano, G. Vecchio, and A. Fusco The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret Oncogene 20 2001 209 218
140. J. Grimm, M. Sachs, S. Britsch, S. Di Cesare, T. Schwarz-Romond, and K. Alitalo Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation J Cell Biol 154 2001 345 354
141. H. Murakami, Y. Yamamura, Y. Shimono, K. Kawai, K. Kurokawa, and M. Takahashi Role of Dok1 in cell signaling mediated by RET tyrosine kinase J Biol Chem 277 2002 32781 32790
142. G. Pelicci, F. Troglio, A. Bodini, R.M. Melillo, V. Pettirossi, and L. Coda The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway Mol Cell Biol 22 2002 7351 7363
143. F. Andreozzi, R.M. Melillo, F. Carlomagno, F. Oriente, C. Miele, and F. Fiory Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase Oncogene 22 2003 2942 2949
144. R.J. Crowder, H. Enomoto, M. Yang, E.M. Johnson Jr., and J. Milbrandt Dok-6, a novel p62 Dok family member, promotes Ret-mediated neurite outgrowth J Biol Chem 279 2004 42072 42081
145. V. Besset, R.P. Scott, and C.F. Ibáñez Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase J Biol Chem 275 2000 39159 39166
146. H. Hayashi, M. Ichihara, T. Iwashita, H. Murakami, Y. Shimono, and K. Kawai Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor Oncogene 19 2000 4469 4475
147. Y. Hayashi, T. Iwashita, H. Murakamai, Y. Kato, K. Kawai, and K. Kurokawa Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN 2A mutation Biochem Biophys Res Commun 281 2001 682 689
148. M. Jijiwa, T. Fukuda, K. Kawai, A. Nakamura, K. Kurokawa, and Y. Murakumo A targeting mutation of tyrosine 1062 in ret causes a marked decrease of enteric neurons and renal hypoplasia Mol Cell Biol 24 2004 8026 8036
149. E. Mercalli, S. Ghizzoni, E. Arighi, L. Alberti, R. Sangregorio, and M.T. Radice Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein Oncogene 20 2001 3475 3485
150. T. Fukuda, K. Kiuchi, and M. Takahashi Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase J Biol Chem 277 2002 19114 19121
151. J.J. Schuringa, K. Wojtachnio, W. Hagens, E. Vellenga, C.H. Buys, and R. Hofstra MEN 2A-RET-induced cellular transformation by activation of STAT3 Oncogene 20 2001 5350 5358
152. D.W. Kim, J.H. Hwang, J.M. Suh, H. Kim, J.H. Song, and E.S. Hwang RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1 Mol Endocrinol 17 2003 1382 1394
153. E.S. Hwang, D.W. Kim, J.H. Hwang, H.S. Jung, J.M. Suh, and Y.J. Park Regulation of STAT1 and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases Mol Endocrinol 18 2004 2672 2684
154. M. Santoro, W.T. Wong, P. Aroca, E. Santos, B. Matoskova, and M. Grieco An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway Mol Cell Biol 14 1994 663 675
155. D.H. van Weering, J.P. Medema, A. van Puijenbroek, B.M. Burgering, P.D. Baas, and J.L. Bos Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells Oncogene 11 1995 2207 2214
156. C.A. Worby, Q.C. Vega, Y. Zhao, H.H. Chao, A.F. Seasholtz, and J.E. Dixon Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase J Biol Chem 271 1996 23619 23622
157. D.H. van Weering, and J.L. Bos Glial cell line-derived neurotrophic factor induces Ret-mediated lamellipodia formation J Biol Chem 272 1997 249 254
158. C. Segouffin-Cariou, and M. Billaud Transforming ability of MEN 2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway J Biol Chem 275 2000 3568 3576
159. K. Maeda, H. Murakami, R. Yoshida, M. Ichihara, A. Abe, and M. Hirai Biochemical and biological responses induced by coupling of Gab1 to phosphatidylinositol 3-kinase in RET-expressing cells Biochem Biophys Res Commun 323 2004 345 354
160. M. Chiariello, R. Visconti, F. Carlomagno, R.M. Melillo, C. Bucci, and V. de Franciscis Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret Oncogene 16 1998 2435 2445
161. K. Kurokawa, K. Kawai, M. Hashimoto, Y. Ito, and M. Takahashi Cell signalling and gene expression mediated by RET tyrosine kinase J Intern Med 253 2003 627 633
162. T. Watanabe, M. Ichihara, M. Hashimoto, K. Shimono, Y. Shimoyama, and T.
163. S. Jain, M.A. Watson, M.K. DeBenedetti, Y. Hiraki, J.F. Moley, and J. Milbrandt Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors Cancer Res 64 2004 3907 3913
164. S.M. Myers, and L.M. Mulligan The RET receptor is linked to stress response pathways Cancer Res 64 2004 4453 4463
165. C. Hedinger, E.D. Williams, and L.H. Sobin The WHO histological classification of thyroid tumors: a commentary on the second edition Cancer 63 1989 908 911
166. Rosai J, Carcangiu ML, DeLellis RA. Atlas of tumor pathology. Tumors of the thyroid gland, 3rd series. Fascicle 5. Washington, DC: Armed Forces Institute of Pathology; 1992.
167. M.A. Pierotti, I. Bongarzone, M.G. Borello, A. Greco, S. Pilotti, and G. Sozzi Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells Genes Chromosomes Cancer 16 1996 1 14
168. S.M. Jhiang The RET proto-oncogene in human cancers Oncogene 19 2000 5590 5597
169. L. Alberti, C. Carniti, C. Miranda, E. Roccato, and M.A. Pierotti RET and NTRK1 proto-oncogenes in human diseases J Cell Physiol 195 2003 168 186
170. M. Ichihara, Y. Murakumo, and M. Takahashi RET and neuroendocrine tumors Cancer Lett 204 2004 197 211
171. M. Santoro, R.M. Melillo, F. Carlomagno, G. Vecchio, and A. Fusco Minireview: RET: normal and abnormal functions Endocrinology 145 2004 5448 5451
172. M. Santoro, R.M. Melillo, F. Carlomagno, A. Fusco, and G. Vecchio Molecular mechanisms of RET activation in human cancer Ann NY Acad Sci 963 2002 116 121
173. F. Sandrini, L. Matyakhina, N.J. Sarlis, L.S. Kirschner, C. Farmakidis, and O. Gimm Regulatory subunit type I-alpha of protein kinase A (PRKAR1A): a tumor-suppressor gene for sporadic thyroid cancer Genes Chromosomes Cancer 35 2002 182 192
174. A. Celetti, A. Cerrato, F. Merolla, D. Vitagliano, G. Vecchio, and M. Grieco H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization Oncogene 23 2004 109 121
175. E. Puxeddu, G. Zhao, J.R. Stringer, M. Medvedovic, S. Moretti, and J.A. Fagin Characterization of novel non-clonal intrachromosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human thyroid cell lines and papillary thyroid cancer specimens Mutat Res 570 2005 17 32
176. E.D. Williams Radiation-induced thyroid cancer Histopathology 23 1993 387 389
177. P. Jacob, G. Goulko, W.F. Heidenreich, I. Likhtarev, I. Kairo, and N.D. Tronko Thyroid cancer risk to children calculated Nature 392 1998 31 32
178. T. Ito, T. Seyama, K.S. Iwamoto, T. Mizuno, N.D. Tronko, and I.V. Komissarenko Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident Lancet 344 1994 259
179. L. Fugazzola, S. Pilotti, A. Pinchera, T.V. Vorontsova, P. Mondellini, and I. Bongarzone Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident Cancer Res 55 1995 5617 5620
180. S. Klugbauer, E. Lengfelder, E.P. Demidchik, and H.M. Rabes High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident Oncogene 11 1995 2459 2467
181. Y.E. Nikiforov, J.M. Rowland, K.E. Bove, H. Monforte-Munoz, and J.A. Fagin Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children Cancer Res 57 1997 1690 1694
182. J. Smida, K. Salassidis, L. Hieber, H. Zitzelsberger, A.M. Kellerer, and E.P. Demidchik Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus Int J Cancer 80 1999 32 38
183. H.M. Rabes, E.P. Demidchik, J.D. Sidorow, E. Lengfelder, C. Beimfohr, and D. Hoelzel Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications Clin Cancer Res 6 2000 1093 1103
184. A. Bounacer, R. Wicker, B. Caillou, A.F. Cailleux, A. Sarasin, and M. Schlumberger High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation Oncogene 15 1997 1263 1273
185. B.J. Collins, G. Chiappetta, A.B. Schneider, M. Santoro, F. Pentimalli, and L. Fogelfeld RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions J Clin Endocrinol Metab 87 2002 3941 3946
186. G.A. Thomas, H. Bunnell, H.A. Cook, E.D. Williams, A. Nerovnya, and E.D. Cherstvoy High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant J Clin Endocrinol Metab 84 1999 4232 4238
187. D.J. Powell Jr., J. Russell, K. Nibu, G. Li, E. Rhee, and M. Liao The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids Cancer Res 58 1998 5523 5528
188. F. Basolo, R. Giannini, C. Monaco, R.M. Melillo, F. Carlomagno, and M. Pancrazi Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma Am J Pathol 160 2002 247 254
189. D. Vitagliano, F. Carlomagno, M.L. Motti, G. Viglietto, Y.E. Nikiforov, and M.N. Nikiforova Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells Cancer Res 64 2004 3823 3829
190. G. Baldassarre, P. Bruni, A. Boccia, G. Salvatore, R.M. Melillo, and M.L. Motti Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1) Oncogene 21 2002 1739 1749
191. M.D. Castellone, V. Guarino, V. De Falco, F. Carlomagno, F. Basolo, and P. Faviana Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas Oncogene 23 2004 5958 5967
192. M.D. Castellone, A. Celetti, V. Guarino, A.M. Cirafici, F. Basolo, and R. Giannini Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells Oncogene 23 2004 2188 2196
193. S. Ashkar, G.F. Weber, V. Panoutsakopoulou, M.E. Sanchirico, M. Jansson, and S. Zawaideh Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity Science 287 2000 860 864
194. D. Chabas, S.E. Baranzini, D. Mitchell, C.C. Bernard, S.R. Rittling, and D.T. Denhardt The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease Science 294 2001 1731 1735
195. M.D. Castellone, A.M. Cirafici, G. De Vita, V. De Falco, L. Malorni, and G. Tallini Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes Oncogene 22 2003 246 255
196. T.L. Buckwalter, A. Venkateswaran, M. Lavender, K.M. La Perle, J.Y. Cho, and M.L. Robinson The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation Oncogene 21 2002 8166 8172
197. G. Viglietto, G. Chiappetta, F.J. Martinez-Tello, F.H. Fukunaga, G. Tallini, and D. Rigopoulou RET/PTC oncogene activation is an early event in thyroid carcinogenesis Oncogene 11 1995 1207 1210
198. G. Tallini, M. Santoro, M. Helie, F. Carlomagno, G. Salvatore, and G. Chiappetta RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes Clin Cancer Res 4 1998 287 294
199. A. Nasir, A.Z. Chaudhry, J. Gillespie, and H.E. Kaiser Papillary microcarcinoma of the thyroid: a clinico-pathologic and prognostic review In Vivo 14 2000 367 376
200. R. Corvi, M. Martinez-Alfaro, H.R. Harach, M. Zini, M. Papotti, and G. Romeo Frequent RET rearrangements in thyroid papillary microcarcinoma detected by interphase fluorescence in situ hybridization Lab Invest 81 2001 1639 1645
201. S. Klugbauer, E.P. Demidchik, E. Lengfelder, and H.M. Rabes Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5 Cancer Res 58 1998 198 203
202. A.H. Fischer, J.A. Bond, P. Taysavang, O.E. Battles, and D. Wynford-Thomas Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure Am J Pathol 153 1998 1443 1450
203. T. Ito, T. Seyama, K.S. Iwamoto, T. Hayashi, T. Mizuno, and N. Tsuyama In vitro irradiation is able to cause RET oncogene rearrangement Cancer Res 53 1993 2940 2943
204. T. Mizuno, S. Kyoizumi, T. Suzuki, K.S. Iwamoto, and T. Seyama Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis Oncogene 15 1997 1455 1460
205. Y.E. Nikiforov, A. Koshoffer, M. Nikiforova, J. Stringer, and J.A. Fagin Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas Oncogene 18 1999 6330 6334
206. M.N. Nikiforova, J.R. Stringer, R. Blough, M. Medvedovic, J.A. Fagin, and Y.E. Nikiforov Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells Science 290 2000 138 141
207. R. Corvi, F. Lesueur, M. Martinez-Alfaro, M. Zini, M. Decaussin, and A. Murat RET rearrangements in familial papillary thyroid carcinomas Cancer Lett 170 2001 191 198
208. F. Lesueur, M. Stark, T. Tocco, H. Ayadi, M.J. Delisle, and D.E. Goldgar Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families, NMTC Consortium J Clin Endocrinol Metab 84 1999 2157 2162
209. O.M. Sheils, J.J. O'eary, V. Uhlmann, K. Lattich, and E.C. Sweeney ret/PTC-1 activation in Hashimoto thyroiditis Int J Surg Pathol 8 2000 185 189
210. M. Di Pasquale, J.L. Rothstein, and J.P. Palazzo Pathologic features of Hashimoto's-associated papillary thyroid carcinomas Hum Pathol 32 2001 24 30
211. S. Arif, A. Blanes, and S.J. Diaz-Cano Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma Histopathology 41 2002 357 362
212. A. Fink, G. Tomlinson, J.L. Freeman, I.B. Rosen, and S.L. Asa Occult micropapillary carcinoma associated with benign follicular thyroid disease and unrelated thyroid neoplasms Mod Pathol 9 1996 816 820
213. M.A. Pierotti, I. Bongarzone, M.G. Borrello, C. Mariani, C. Miranda, and G. Sozzi Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas J Endocrinol Invest 18 1995 130 133
214. D. Martin-Zanca, S.H. Hughes, and M. Barbacid A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences Nature 319 1986 743 748
215. A. Greco, M.A. Pierotti, I. Bongarzone, S. Pagliardini, C. Lanzi, and G. Della Porta TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas Oncogene 7 1992 237 242
216. A. Greco, C. Mariani, C. Miranda, A. Lupas, S. Pagliardini, and M. Pomati The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain Mol Cell Biol 15 1995 6118 6127
217. A. Greco, C. Miranda, S. Pagliardini, L. Fusetti, I. Bongarzone, and M.A. Pierotti Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes Genes Chromosomes Cancer 19 1997 112 123
218. R. Ciampi, J.A. Knauf, R. Kerler, M. Gandhi, Z. Zhu, and M.N. Nikiforova Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer J Clin Invest 115 2005 94 101
219. M. Takahashi, H. Shibata, M. Shimakawa, M. Miyamoto, H. Mukai, and Y. Ono Characterization of a novel giant scaffolding protein, CG-NAP, that anchors multiple signaling enzymes to centrosome and the Golgi apparatus J Biol Chem 274 1999 17267 17274
220. A. Fusco, G. Viglietto, and M. Santoro A new mechanism of BRAF activation in human thyroid papillary carcinomas J Clin Invest 115 2005 20 23
221. E.T. Kimura, M.N. Nikiforova, Z. Zhu, J.A. Knauf, Y.E. Nikiforov, and J.A. Fagin High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma Cancer Res 63 2003 1454 1457
222. X. Xu, R.M. Quiros, P. Gattuso, K.B. Ain, and R.A. Prinz High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines Cancer Res 63 2003 4561 4567
223. E. Puxeddu, S. Moretti, R. Elisei, C. Romei, R. Pascucci, and M. Martinelli BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas J Clin Endocrinol Metab 89 2004 2414 2420
224. N.J. Dibb, S.M. Dilworth, and C.D. Mol Switching on kinases: oncogenic activation of BRAF and the PDGFR family Nat Rev Cancer 4 2004 718 727
225. M.N. Nikiforova, R. Ciampi, G. Salvatore, M. Santoro, M. Gandhi, and J.A. Knauf Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas Cancer Lett 209 2004 1 6
226. J. Lima, V. Trovisco, P. Soares, V. Maximo, J. Magalhaes, and G. Salvatore BRAF mutations are not a major event in post-chernobyl childhood thyroid carcinomas J Clin Endocrinol Metab 89 2004 4267 4271
227. M. Frattini, C. Ferrario, P. Bressan, D. Balestra, L. De Cecco, and P. Mondellini Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer Oncogene 23 2004 7436 7440
228. H. Namba, S.A. Rubin, and J.A. Fagin Point mutations of ras oncogenes are an early event in thyroid tumorigenesis Mol Endocrinol 4 1990 1474 1479
229. C.T. Esapa, S.J. Johnson, P. Kendall-Taylor, T.W. Lennard, and P.E. Harris Prevalence of Ras mutations in thyroid neoplasia Clin Endocrinol (Oxf) 50 1999 529 535
230. R.A. DeLellis Multiple endocrine neoplasia syndromes revisited. Clinical, morphologic, and molecular features Lab Invest 72 1995 494 505
231. P.J. Goodfellow, and SA. Wells Jr. RET gene and its implications for cancer J Natl Cancer Inst 87 1995 1515 1523
232. S.I. Sherman Thyroid carcinoma Lancet 361 2003 501 511
233. M.L. Brandi, R.F. Gagel, A. Angeli, J.P. Bilezikian, P. Beck-Peccoz, and C. Bordi Guidelines for diagnosis and therapy of MEN type 1 and type 2 J Clin Endocrinol Metab 86 2001 5658 5671
234. C. Eng, D. Clayton, I. Schuffenecker, G. Lenoir, G. Cote, and R.F. Gagel The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2, International RET mutation consortium analysis JAMA 276 1996 1575 1579
235. V. Nunziata, G. di Giovanni, A.M. Lettera, M. D'Armiento, and M. Mancini Cutaneous lichen amyloidosis associated with multiple endocrine neoplasia type 2A Henry Ford Hosp Med J 37 1989 144 146
236. D.T. Donovan, M.L. Levy, E.J. Furst, B.R. Alford, T. Wheeler, and J.A. Tschen Familial cutaneous lichen amyloidosis in association with multiple endocrine neoplasia type 2A: a new variant Henry Ford Hosp Med J 37 1989 147 150
237. M. Verdy, A.M. Weber, C.C. Roy, C.L. Morin, M. Cadotte, and P. Brochu Hirschsprung's disease in a family with multiple endocrine neoplasia type 2 J Pediatr Gastroenterol Nutr 1 1982 603 607
238. L.M. Mulligan, C. Eng, T. Attié, S. Lyonnet, D.J. Marsh, and V.J. Hyland Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene Hum Mol Genet 3 1994 2163 2167
239. R.A. Decker, M.L. Peacock, and P. Watson Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation Hum Mol Genet 7 1998 129 134
240. H. Donis-Keller, S. Dou, D. Chi, K.M. Carlson, K. Toshima, and T.C. Lairmore Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC Hum Mol Genet 2 1993 851 856
241. L.M. Mulligan, J.B. Kwok, C.S. Healey, M.J. Elsdon, C. Eng, and E. Gardner Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A Nature 363 1993 458 460
242. K.M. Carlson, S. Dou, D. Chi, N. Scavarda, K. Toshima, and C.E. Jackson Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B Proc Natl Acad Sci USA 91 1994 1579 1583
243. C. Eng, D.P. Smith, L.M. Mulligan, M.A. Nagai, C.S. Healey, and M.A. Ponder Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours Hum Mol Genet 3 1994 237 241
244. R.M. Hofstra, R.M. Landsvater, I. Ceccherini, R.P. Stulp, T. Stelwagen, and Y. Luo A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma Nature 367 1994 375 376
245. M. Santoro, F. Carlomagno, A. Romano, D.P. Bottaro, N.A. Dathan, and M. Grieco Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B Science 267 1995 381 383
246. M.G. Borrello, D.P. Smith, B. Pasini, I. Bongarzone, A. Greco, and M.J. Lorenzo RET activation by germline MEN 2A and MEN 2B mutations Oncogene 11 1995 2419 2427
247. N. Asai, T. Iwashita, M. Matsuyama, and M. Takahashi Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations Mol Cell Biol 15 1995 1613 1619
248. F.M. Michiels, S. Chappuis, B. Caillou, A. Pasini, M. Talbot, and R. Monier Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation Proc Natl Acad Sci USA 94 1997 3330 3335
249. D.A. Sweetser, G.J. Froelick, A.M. Matsumoto, K.E. Kafer, B. Marck, and R.D. Palmiter Ganglioneuromas and renal anomalies are induced by activated RET(MEN 2B) in transgenic mice Oncogene 18 1999 877 886
250. C. Gestblom, D.A. Sweetser, B. Doggett, and R.P. Kapur Sympathoadrenal hyperplasia causes renal malformations in Ret(MEN 2B)-transgenic mice Am J Pathol 155 1999 2167 2179
251. D.S. Acton, D. Velthuyzen, C.J. Lips, and J.W. Höppener Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice Oncogene 19 2000 3121 3125
252. K. Kawai, T. Iwashita, H. Murakami, N. Hiraiwa, A. Yoshiki, and M. Kusakabe Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation Cancer Res 60 2000 5254 5260
253. C.L. Smith-Hicks, K.C. Sizer, J.F. Powers, A.S. Tischler, and F. Costantini C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B EMBO J 19 2000 612 622
254. L. Reynolds, K. Jones, D.J. Winton, A. Cranston, C. Houghton, and L. Howard C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET Oncogene 20 2001 3986 3994
255. I. Rajan, C. Gestblom, and R.P. Kapur RET(MEN 2B)-transgene produces sympathoadrenal tumors but does not prevent intestinal aganglionosis in gdnf-/- or gfr alpha-1(-/-) mice Pediatr Dev Pathol 4 2001 446 453
256. B. Pasini, I. Ceccherini, and G. Romeo RET mutations in human disease Trends Genet 12 1996 138 144
257. W. Hoppner, and M.M. Ritter A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A Hum Mol Genet 6 1997 587 590
258. W. Hoppner, H. Dralle, and G. Brabant Duplication of 9 base pairs in the critical cysteine-rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A Hum Mutat 1 1998 S128 S130
259. A. Tessitore, A.A. Sinisi, D. Pasquali, M. Cardone, D. Vitale, and A. Bellastella A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene J Clin Endocrinol Metab 84 1999 3522 3527
260. S.C. Huang, C.A. Koch, A.O. Vortmeyer, S.D. Pack, U.D. Lichtenauer, and P. Mannan Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas Cancer Res 60 2000 6223 6226
261. S.C. Huang, J. Torres-Cruz, S.D. Pack, C.A. Koch, A.O. Vortmeyer, and P. Mannan Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma J Clin Endocrinol Metab 88 2003 459 463
262. C. Jimenez, M.A. Habra, S.C. Huang, A. El-Naggar, S.E. Shapiro, and D.B. Evans Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation J Clin Endocrinol Metab 89 2004 4142 4145
263. P. Pigny, C. Bauters, J.L. Wemeau, M.L. Houcke, M. Crepin, and P. Caron A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma J Clin Endocrinol Metab 84 1999 1700 1704
264. A.M. Da Silva, R.M. Maciel, M.R. Da Silva, S.R. Toledo, M.B. De Carvalho, and J.M. Cerutti A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma J Clin Endocrinol Metab 88 2004 5438 5443
265. L. Kasprzak, S. Nolet, L. Gaboury, C. Pavia, C. Villabona, and F. Rivera-Fillat Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET J Med Genet 38 2001 784 787
266. D.P. Smith, C. Houghton, and B.A. Ponder Germline mutation of RET codon 883 in two cases of de novo MEN 2B Oncogene 15 1997 1213 1217
267. K.M. Carlson, J. Bracamontes, C.E. Jackson, R. Clark, A. Lacroix, and S.A. Wells Jr. Parent-of-origin effects in multiple endocrine neoplasia type 2B Am J Hum Genet 55 1994 1076 1082
268. A. Miyauchi, H. Futami, N. Hai, T. Yokozawa, K. Kuma, and N. Aoki Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation Jpn J Cancer Res 90 1999 1 5
269. F. Carlomagno, G. Salvatore, A.M. Cirafici, G. De Vita, R.M. Melillo, and V. de Franciscis The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype Cancer Res 57 1997 391 395
270. S. Ito, T. Iwashita, N. Asai, H. Murakami, Y. Iwata, and G. Sobue Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype Cancer Res 57 1997 2870 2872
271. S. Chappuis-Flament, A. Pasini, G. De Vita, C. Ségouffin-Cariou, A. Fusco, and T. Attié Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines Oncogene 17 1998 2851 2861
272. A. Pasini, O. Geneste, P. Legrand, M. Schlumberger, M. Rossel, and L. Fournier Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain Oncogene 15 1997 393 402
273. T. Iwashita, M. Kato, H. Murakami, N. Asai, Y. Ishiguro, and S. Ito Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma Oncogene 18 1999 3919 3922
274. L.E. Marengere, Z. Songyang, G.D. Gish, M.D. Schaller, J.T. Parsons, and M.J. Stern SH2 domain specificity and activity modified by a single residue Nature 369 1994 502 505
275. Z. Songyang, K.L. Carraway III, M.J. Eck, S.C. Harrison, R.A. Feldman, and M. Mohammadi Catalytic specificity of protein-tyrosine kinases is critical for selective signalling Nature 373 1995 536 539
276. S.D. Pandit, H. Donis-Keller, T. Iwamoto, J.M. Tomich, and L.J. Pike The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor J Biol Chem 271 1996 5850 5858
277. H. Murakami, T. Iwashita, N. Asai, Y. Shimono, Y. Iwata, and K. Kawai Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation Biochem Biophys Res Commun 262 1999 68 75
278. D. Salvatore, R.M. Melillo, C. Monaco, R. Visconti, G. Fenzi, and G. Vecchio Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B Cancer Res 61 2001 1426 1431
279. I. Bongarzone, E. Vigano, L. Alberti, M.G. Borrello, B. Pasini, and A. Greco Full activation of MEN 2B mutant RET by an additional MEN 2A mutation or by ligand GDNF stimulation Oncogene 16 1998 2295 2301
280. J.M. Rey, J.P. Brouillet, J. Fonteneau-Allaire, A. Boneu, D. Bastie, and T. Maudelonde Novel germline RET mutation segregating with papillary thyroid carcinomas Genes Chromosomes Cancer 32 2001 390 391
281. R.M. Melillo, A.M. Cirafici, V. De Falco, M. Bellantoni, G. Chiappetta, and A. Fusco The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma Am J Pathol 165 2004 511 521
282. G.L. Feldman, M.W. Edmonds, P.J. Ainsworth, I. Schuffenecker, G.M. Lenoir, and A.W. Saxe Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG → ATG) mutation Surgery 28 2000 93 98
283. M. Brauckhoff, O. Gimm, R. Hinze, J. Ukkat, K. Brauckhoff, and H. Dralle Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation Thyroid 12 2002 557 561
284. G. Papi, S. Corrado, M.G. Pomponi, C. Carapezzi, A. Cesinaro, and V.A. LiVolsi Concurrent lymph node metastases of medullary and papillary thyroid carcinoma in a case with RET oncogene germline mutation Endocr Pathol 14 2003 269 276
285. F. Orlandi, E. Chiefari, P. Caraci, A. Mussa, I. Gonzatto, and P. De Giuli RET proto-oncogene mutation in a mixed medullary-follicular thyroid carcinoma J Endocrinol Invest 24 2001 51 55
286. C.S. Kovacs, R.M. Mase, K. Kovacs, G.K. Nguyen, and C.L. Chik Thyroid medullary carcinoma with thyroglobulin immunoreactivity in sporadic multiple endocrine neoplasia type 2-B Cancer 74 1994 928 932
287. M. Wiench, Z. Wygoda, E. Gubala, J. Wloch, K. Lisowska, and J. Krassowski Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients J Clin Oncol 19 2001 1374 1380
288. L. Gil, M. Azanedo, M. Pollan, E. Cristobal, B. Arribas, and L. Garcia-Albert Genetic analysis of RET, GFR alpha 1 and GDNF genes in Spanish families with multiple endocrine neoplasia type 2A Int J Cancer 99 2002 299 304
289. J.B. Vanhorne, S.D. Andrew, K.J. Harrison, S.A. Taylor, B. Thomas, and T.J. McDonald A model for GFRalpha4 function and a potential modifying role in multiple endocrine neoplasia 2 Oncogene 24 2005 1091 1097
290. J. Zedenius, G. Wallin, B. Hamberger, M. Nordenskjold, G. Weber, and C. Larsson Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s Hum Mol Genet 3 1994 1259 1262
291. C. Eng, D.P. Smith, L.M. Mulligan, C.S. Healey, M.J. Zvelebil, and T.J. Stonehouse A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC Oncogene 10 1995 509 513
292. C. Eng, L.M. Mulligan, C.S. Healey, C. Houghton, A. Frilling, and F. Raue Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma Cancer Res 56 1996 2167 2170
293. D.J. Marsh, D.L. Learoyd, S.D. Andrew, L. Krishnan, R. Pojer, and A.L. Richardson Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma Clin Endocrinol (Oxf) 44 1996 249 257
294. C. Romei, R. Elisei, A. Pinchera, I. Ceccherini, E. Molinaro, and F. Mancusi Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence J Clin Endocrinol Metab 81 1996 1619 1622
295. M.J. Bugalho, J.P. Frade, J.R. Santos, E. Limbert, and L. Sobrinho Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain Eur J Endocrinol 136 1997 423 426
296. S. Shirahama, K. Ogura, H. Takami, K. Ito, T. Tohsen, and A. Miyauchi Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma J Hum Genet 43 1998 101 106
297. V.N. Kalinin, F.A. Amosenko, M.A. Shabanov, L.N. Lubchenko, S.B. Hosch, and R.F. Garkavtseva Three novel mutations in the RET proto-oncogene J Mol Med 79 2001 609 612
298. T. Schilling, J. Burck, H.P. Sinn, A. Clemens, H.F. Otto, and W. Hoppner Prognostic value of codon 918 (ATG → ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma Int J Cancer 95 2001 62 66
299. C.J. Lips Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease J Intern Med 243 1998 589 594
300. O. Gimm, T. Sutter, and H. Dralle Diagnosis and therapy of sporadic and familial medullary thyroid carcinoma J Cancer Res Clin Oncol 127 2001 156 165
301. G. Freyer, B. Ligneau, M. Schlumberger, C. Blandy, B. Contedevolx, and V. Trillet-Lenoir Quality of life in patients at risk of medullary thyroid carcinoma and followed by a comprehensive medical network: trends for future evaluations Ann Oncol 12 2001 1461 1465
302. M.S. Cohen, and J.F. Moley Surgical treatment of medullary thyroid carcinoma J Intern Med 253 2003 616 626
303. S.A. Wells Jr., and C. Franz Medullary carcinoma of the thyroid gland World J Surg 24 2000 952 956
304. S.A. Wells, and J.R. Nevins Evolving strategies for targeted cancer therapy - past, present, and future J Natl Cancer Inst 96 2004 980 981
305. J.A. Fagin How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy J Endocrinol 183 2004 249 256
306. M.S. Cohen, H.B. Hussain, and J.F. Moley Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors Surgery 132 2002 960 966
307. C. Lanzi, G. Cassinelli, T. Pensa, M. Cassinis, R.A. Gambetta, and M.G. Borrello Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative Int J Cancer 85 2000 384 390
308. C. Lanzi, G. Cassinelli, G. Cuccuru, N. Zaffaroni, R. Supino, and S. Vignati Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1 Cell Mol Life Sci 60 2003 1449 1459
309. S. Ezzat, P. Huang, A. Dackiw, and S.L. Asa Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth Clin Cancer Res 11 2005 1336 1341
310. G. Cuccuru, C. Lanzi, G. Cassinelli, G. Pratesi, M. Tortoreto, and G. Petrangolini Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN 2A-associated medullary thyroid carcinoma J Natl Cancer Inst 96 2004 1006 1014
311. C.J. Strock, J.I. Park, M. Rosen, C. Dionne, B. Ruggeri, and S. Jones-Bolin CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth Cancer Res 63 2003 5559 5563
312. F. Carlomagno, D. Vitagliano, T. Guida, M. Napolitano, G. Vecchio, and A. Fusco The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes Cancer Res 62 2002 1077 1082
313. C. Carniti, C. Perego, P. Mondellini, M.A. Pierotti, and I. Bongarzone PP1 inhibitor induces degradation of RETMEN 2A and RETMEN 2B oncoproteins through proteosomal targeting Cancer Res 63 2003 2234 2243
314. F. Carlomagno, D. Vitagliano, T. Guida, F. Basolo, M.D. Castellone, and R.M. Melillo Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) J Clin Endocrinol Metab 88 2003 1897 1902
315. F. Carlomagno, D. Vitagliano, T. Guida, F. Ciardiello, G. Tortora, and G. Vecchio ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Res 62 2002 7284 7290
316. F. Carlomagno, T. Guida, S. Anaganti, G. Vecchio, A. Fusco, and A.J. Ryan Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors Oncogene 23 2004 6056 6063
317. L. Cerchia, D. Libri, M.S. Carlomagno, and V. de Franciscis The soluble ectodomain of RetC634Y inhibits both the wild-type and the constitutively active Ret Biochem J 372 2003 897 903
318. M. Drosten, A. Frilling, T. Stiewe, and B.M. Pützer A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant Surgery 132 2002 991 997
319. M. Drosten, T. Stiewe, and B.M. Pützer Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model Hum Gene Ther 14 2003 971 982
320. M. Drosten, G. Hilken, M. Bockmann, F. Rodicker, N. Mise, and A.N.
321. M.A. Parisi, and R.P. Kapur Genetics of Hirschsprung disease Curr Opin Pediatr 12 2000 610 617
322. R.K. Goyal, and I. Hirano The enteric nervous system N Engl J Med 334 1996 1106 1115
323. M.D. Gershon Genes and lineages in the formation of the enteric nervous system Curr Opin Neurobiol 7 1997 101 109
324. S. Taraviras, and V. Pachnis Development of the mammalian enteric nervous system Curr Opin Genet Dev 9 1999 321 327
325. J. Amiel, and S. Lyonnet Hirschsprung disease, associated syndromes, and genetics: a review J Med Genet 38 2001 729 739
326. P. Edery, A. Pelet, L.M. Mulligan, L. Abel, T. Attié, and E. Dow Long segment and short segment familial Hirschsprung's disease: variable clinical expression at the RET locus J Med Genet 31 1994 602 606
327. M. Angrist, S. Bolk, B. Thiel, E.G. Puffenberger, R.M. Hofstra, and C.H. Buys Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease Hum Mol Genet 4 1995 821 830
328. T. Attié, A. Pelet, P. Edery, C. Eng, L.M. Mulligan, and J. Amiel Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease Hum Mol Genet 4 1995 1381 1386
329. C. Eng The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease N Engl J Med 335 1996 943 951
330. S.M. Myers, R. Salomon, A. Goessling, A. Pelet, C. Eng, and A. von Deimling Investigation of germline GFR alpha-1 mutations in Hirschsprung disease J Med Genet 36 1999 217 220
331. L. Shen, J.G. Pichel, T. Mayeli, H. Sariola, B. Lu, and H. Westphal Gdnf haploinsufficiency causes Hirschsprung-like intestinal obstruction and early-onset lethality in mice Am J Hum Genet 70 2002 435 447
332. V. Cacheux, F. Dastot-Le Moal, H. Kääriäinen, N. Bondurand, R. Rintala, and B. Boissier Loss-of-function mutations in SIP1 Smad interacting protein 1 result in a syndromic Hirschsprung disease Hum Mol Genet 10 2001 1503 1510
333. N. Wakamatsu, Y. Yamada, K. Yamada, T. Ono, N. Nomura, and H. Taniguchi Mutations in SIP1, encoding Smad interacting protein-1, cause a form of Hirschsprung disease Nat Genet 27 2001 369 370
334. S. Bolk, A. Pelet, R.M. Hofstra, M. Angrist, R. Salomon, and D. Croaker A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus Proc Natl Acad Sci USA 97 2000 268 273
335. S.B. Gabriel, R. Salomon, A. Pelet, M. Angrist, J. Amiel, and M. Fornage Segregation at three loci explains familial and population risk in Hirschsprung disease Nat Genet 31 2002 89 93
336. S. Borrego, M.E. Sáez, A. Ruiz, O. Gimm, M. López-Alonso, and G. Antiñolo Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression J Med Genet 36 1999 771 774
337. S. Borrego, A. Ruiz, M.E. Sáez, O. Gimm, X. Gao, and M. López-Alonso RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease J Med Genet 37 2000 572 578
338. S. Borrego, F.A. Wright, R.M. Fernández, N. Williams, M. López-Alonso, and R. Davuluri A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma Am J Hum Genet 72 2003 88 100
339. R. Gath, A. Goessling, K.M. Keller, S. Koletzko, W. Coerdt, and H. Muntefering Analysis of the RET, GDNF, EDN3, and EDNRB genes in patients with intestinal neuronal dysplasia and Hirschsprung disease Gut 48 2001 671 675
340. G. Fitze, M. Schreiber, E. Kuhlisch, H.K. Schackert, and D. Roesner Association of RET protooncogene codon 45 polymorphism with Hirschsprung disease Am J Hum Genet 65 1999 1469 1473
341. G. Fitze, J. Cramer, A. Ziegler, M. Schierz, M. Schreiber, and E. Kuhlisch Association between c135G/A genotype and RET proto-oncogene germline mutations and phenotype of Hirschsprung's disease Lancet 359 2002 1200 1205
342. G. Fitze, M. Schierz, E. Kuhlisch, M. Schreiber, A. Ziegler, and D. Roesner Novel intronic polymorphisms in the RET proto-oncogene and their association with Hirschsprung disease Hum Mutat 22 2003 177
343. M. Sancandi, P. Griseri, B. Pesce, G. Patrone, F. Puppo, and M. Lerone Single nucleotide polymorphic alleles in the 5′ region of the RET proto-oncogene define a risk haplotype in Hirschsprung's disease J Med Genet 40 2003 714 718
344. D. Newgreen, and H.M. Young Enteric nervous system: development and developmental disturbances Pediatr Dev Pathol 5 2002 224 247
345. M.M. Carrasquillo, A.S. McCallion, E.G. Puffenberger, C.S. Kashuk, N. Nouri, and A. Chakravarti Genome-wide association study and mouse model identify interaction between RET and EDNRB pathways in Hirschsprung disease Nat Genet 32 2002 237 244
346. A.S. McCallion, E. Stames, R.A. Conlon, and A. Chakravarti Phenotype variation in two-locus mouse models of Hirschsprung disease: tissue-specific interaction between Ret and Ednrb Proc Natl Acad Sci USA 100 2003 1826 1831
347. T. Iwashita, G.M. Kruger, R. Pardal, M.J. Kiel, and S.J. Morrison Hirschsprung disease is linked to defects in neural crest stem cell function Science 301 2003 972 996
348. G.M. Kruger, J.T. Mosher, Y.H. Tsai, K.J. Yeager, T. Iwashita, and C.E. Gariepy Temporally distinct requirements for endothelin receptor B in the generation and migration of gut neural crest stem cells Neuron 40 2003 917 929
349. A. Barlow, E. de Graaff, and V. Pachnis Enteric nervous system progenitors are coordinately controlled by the G protein-coupled receptor EDNRB and the receptor tyrosine kinase RET Neuron 40 2003 905 916
350. C. Eng, and L.M. Mulligan Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease Hum Mutat 9 1997 97 109
351. T. Iwashita, K. Kurokawa, S. Qiao, H. Murakami, N. Asai, and K. Kawai Functional analysis of RET with Hirschsprung mutations affecting its kinase domain Gastroenterology 121 2001 24 33
352. A. Pelet, O. Geneste, P. Edery, A. Pasini, S. Chappuis, and T. Atti Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease J Clin Invest 101 1998 1415 1423
353. F. Carlomagno, G. De Vita, M.T. Berlingieri, V. de Franciscis, R.M. Melillo, and V. Colantuoni Molecular heterogeneity of RET loss of function in Hirschsprung's disease EMBO J 15 1996 2717 2725
354. T. Iwashita, H. Murakami, N. Asai, and M. Takahashi Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain Hum Mol Genet 5 1996 1577 1580
355. E. Arighi, A. Popsueva, D. Degl'Innocenti, M.G. Borrello, C. Carniti, and N.M. Perala Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease Mol Endocrinol 18 2004 1004 1017
356. M. Takahashi, T. Iwashita, M. Santoro, S. Lyonnet, G.M. Lenoir, and M. Billaud Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function? Hum Mutat 13 1999 331 336
357. B. Pasini, M.G. Borrello, A. Greco, I. Bongarzone, Y. Luo, and P. Mondellini Loss of function effect of RET mutations causing Hirschsprung disease Nat Genet 10 1995 35 40
358. O. Geneste, C. Bidaud, G. De Vita, R.M. Hofstra, S. Tartare-Deckert, and C.H. Buys Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site Hum Mol Genet 8 1999 1989 1999
359. M.P. Cosma, M. Cardone, F. Carlomagno, and V. Colantuoni Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism Mol Cell Biol 18 1998 3321 3329
360. M.C. Bordeaux, C. Forcet, L. Granger, V. Corset, C. Bidaud, and M. Billaud The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease EMBO J 19 2000 4056 4063
361. L.M. Mulligan, D.J. Marsh, B.G. Robinson, I. Schuffenecker, J. Zedenius, and C.J. Lips Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium J Intern Med 238 1995 343 346
362. P. Igaz, A. Patocs, K. Racz, I. Klein, A. Varadi, and O. Esik Occurrence of pheochromocytoma in a MEN 2A family with codon 609 mutation of the RET proto-oncogene J Clin Endocrinol Metab 87 2002 2994
363. M. Nishikawa, Y. Murakumo, T. Imai, K. Kawai, M. Nagaya, and H. Funahashi Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease Eur J Hum Genet 11 2003 364 368
364. H. Morita, H. Daidoh, K. Nagata, Y. Okano, Y. Sudoh, and T. Maruyama A family of multiple endocrine neoplasia type 2A: genetic analysis and clinical features Endocr J 43 1996 25 30
365. D.J. Marsh, B.G. Robinson, S. Andrew, A.L. Richardson, R. Pojer, and M. Schnitzler A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families Genomics 23 1994 477 479
366. S. Oishi, T. Sato, S. Takiguchi-Shirahama, and Y. Nakamura Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome) Endocr J 42 1995 527 536
367. P. Komminoth, E.K. Kunz, X. Matias-Guiu, O. Hiort, G. Christiansen, and A. Colomer Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas Cancer 76 1995 479 489
368. M. Poturnajova, V. Altanerova, L. Kostalova, J. Breza, and C. Altaner Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome J Mol Med 2004
369. I. Berndt, M. Reuter, B. Saller, K. Frank-Raue, P. Groth, and M. Grußendorf A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A J Clin Endocrinol Metab 83 1998 770 774
370. A. Bolino, I. Schuffenecker, Y. Luo, M. Seri, M. Silengo, and T. Tocco RET mutations in exons 13 and 14 of FMTC patients Oncogene 10 1995 2415 2419
371. O. Fattoruso, L. Quadro, A. Libroia, U. Verga, G. Lupoli, and E. Cascone A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma Hum Mutat 1 1998 S167 S171
372. R.M. Hofstra, O. Fattoruso, L. Quadro, Y. Wu, A. Libroia, and U. Verga A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma J Clin Endocrinol Metab 82 1997 4176 4178